Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestin presented as a 20 µg/day (52 mg total) levonorgestrel‑releasing intrauterine system for intrauterine use. It provides long‑acting reversible contraception and reduces heavy menstrual bleeding in women of reproductive age, offering up to five years of protection.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures reliable access to quality‑controlled devices for reproductive health management. All shipments comply with international regulatory standards and are tracked to guarantee timely delivery.

Mirena, a levonorgestrel‑releasing intrauterine system, is used within the hormonal contraceptive pathway for reproductive health management.

Contraception: provides up to five years of highly effective reversible birth control. Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with menorrhagia. Endometrial protection: induces endometrial atrophy, decreasing the risk of hyperplasia in women using estrogen therapy. Endometriosis‑related pain: may alleviate dysmenorrhea by suppressing ovulation and thinning the endometrium.

Levonorgestrel IUS may be associated with a range of adverse reactions, ranging from mild to serious.

Common Side Effects: - Irregular bleeding: spotting or breakthrough bleeding during the first 3‑6 months as the endometrium adapts. - Amenorrhea: absence of menstrual periods after the initial adjustment period. - Pelvic pain: mild cramping or discomfort that usually resolves within weeks. - Headache: occasional tension‑type headache, often transient.

Serious or Rare Side Effects: - Uterine perforation: rare injury occurring during insertion that may require surgical repair. - Expulsion: device may be expelled spontaneously, necessitating re‑evaluation. - Infection: pelvic inflammatory disease or endometritis can develop if aseptic technique is compromised. - Hormone‑related thromboembolism: very rare clotting events that require immediate medical attention.

Before Mirena insertion, clinicians should consider several safety measures.

Screen for pregnancy: ensure the patient is not pregnant before insertion. Assess uterine anomalies: avoid use in abnormal uterine cavity or active infection. Monitor for expulsion: advise the patient to check strings regularly and report changes. Consider hormonal contraindications: avoid in women with known thrombophilia or hormone‑sensitive cancers. Inform about return of fertility: fertility resumes promptly after device removal. Store at room temperature: keep device in original packaging, protect from moisture and extreme temperatures.

Levonorgestrel released from an intrauterine system can interact with other medicines that affect hormone metabolism.

Major Interactions (Avoid): - Enzyme inducers: strong CYP3A4 inducers (e.g., rifampicin) may reduce levonorgestrel efficacy. - Antifungal agents: concurrent use of ketoconazole can increase systemic levonorgestrel levels, potentially raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Antiepileptics: carbamazepine or phenytoin may modestly lower levonorgestrel concentrations. - Antibiotics: broad‑spectrum antibiotics such as tetracycline may have minimal effect, but monitoring is advised. - Herbal supplements: St. John’s wort may decrease hormone levels, possibly reducing contraceptive effectiveness.